Ankylosing spondylitis and systemic sclerosis: a rare combination.
We report a case of diffuse systemic sclerosis (skin, joints, esophagus, and Raynaud's phenomenon) in a 41-year-old Caucasian male with a 15-year history of ankylosing spondylitis and an episode of severe myocarditis of unknown origin. His HLA type included both the B27 allele conferring susceptibility to ankylosing spondylitis and the B35, DRB1 11, and DQB1 03 described as associated with systemic sclerosis. This case-report confirms that two inflammatory joint diseases may co-exist, particularly in patients carrying one or two susceptibility alleles to both diseases.
Ouédraogo
Dieu-Donné
DD
Service de Rhumatologie, CHU Bichat-Claude Bernard, 46 rue Henri Huchard, 75877 Paris Cedex 18, France.
Palazzo
Elisabeth
E
Nlomé-Nzé
Mireille
M
Somogyi-Demerjian
Nathalie
N
Meyer
Olivier
O
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D015235:HLA-B Antigens / Q000235:genetics; D006650:Histocompatibility Testing; D006801:Humans; D008297:Male; D010396:Penicillamine / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D012595:Scleroderma, Systemic / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D013167:Spondylitis, Ankylosing / Q000150:complications* / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D018501:Antirheumatic Agents; D015235:HLA-B Antigens; D010396:Penicillamine; D011241:Prednisone